A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy

BACKGROUND: For extreme hereditary hemorrhagic telangiectasia (HHT) disease, treatments such as intravenous bevacizumab are often utilized. However, whether its efficacy is similar across diverse races and ethnicities is unclear. METHODS: In this systematic review, we performed a search for English-...

Descripción completa

Detalles Bibliográficos
Autores principales: Galiatsatos, Panagis, Wilson, Cheri, O’Brien, Jaime, Gong, Anna J., Angiolillo, Dylan, Johnson, James, Myers, Carlie, Strout, Sara, Mathai, Stephen, Robinson, Gina, Rowan, Nicholas R., Weiss, Clifford R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195340/
https://www.ncbi.nlm.nih.gov/pubmed/35698080
http://dx.doi.org/10.1186/s13023-022-02371-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195340/
https://www.ncbi.nlm.nih.gov/pubmed/35698080
http://dx.doi.org/10.1186/s13023-022-02371-0

Ejemplares similares